Lead Biomedical Innovations: Join CLYTE's Biomedical Device Beta Testing Program

1.0: Medical innovations image by British Columbia Medical Journal

Are you a biomedical researcher driving progress in healthcare, medicine, or drug discovery? CLYTE LLC invites pioneering labs engaged in cutting-edge biomedical research to join our First Client Initiative (FCI) – a premier biomedical device beta testing program. This is your chance to gain exclusive, early access to biomedical innovations before they reach the market and play a crucial role in refining tools that shape the future.

Gain Early Access Through Our Biomedical Device Beta Testing Opportunity

The FCI program offers selected partners a unique opportunity: receive a supply of our latest premarket devices, free of charge, for up to one year. Your participation in this biomedical device beta testing initiative involves providing essential feedback and performance data, helping us perfect these tools for the demanding biomedical research landscape. The program operates in approximately two-month testing cycles, providing up to 5 units per cycle. Extensions are possible based on mutual agreement, product availability, and progress towards commercial readiness. While the innovative devices are complimentary, participants cover shipping costs.

Final Call: CellCut 3.0 Biomedical Device Beta Testing Cycle

CellCut 3.0: Perform 48 well scratch assays all at once with consistency

We are opening the final 1-2 month biomedical device beta testing cycle for CellCut before its planned commercial launch around June 2025. CellCut is a device hat allows researchers perform cell migration / healing / 2D scratch assays with higher ease and efficiency. This is the last chance for biomedical researchers to work directly with CellCut in its premarket stage, offering feedback crucial for its final development – a key step in bringing biotechnological innovations from the from our labs to the wider research community.

Your Expertise Drives Biomedical Innovations

As these are beta products integral to ongoing biomedical innovations, they are still undergoing refinement and may not exhibit full final functionality. Your expert feedback as biomedical researchers is vital. For this CellCut biomedical device beta testing cycle, we aim to gather specific usability metrics related to:

1. Operational consistency: Average non-scratched wells across operators.

2. Scratching accuracy: Frequency of unusable scratches (too thick/narrow/doubled).

3. User adaptation: Improvement rates over a three-week period.

4. Overall user experience: Qualitative observations from your research team.

This feedback directly impacts tools used in critical fields like drug discovery and medicine.

Collaborative Partnership in Biomedical Research

Our biomedical device beta testing program operates as a true partnership. A mutual Non-Disclosure Agreement (NDA) protects all parties. To support future biomedical innovations, we request that publications stemming from biomedical research using our products acknowledge CLYTE's contribution. Throughout the cycle, our engineering team provides support, and limited access to expert biomedical consultants is available for assay design assistance, ensuring a productive biomedical device beta testing experience.   

Apply for our First Client Initiative Biomedical Device Beta Testing Program Today!

Influence the next wave of tools impacting medicine and healthcare research. Apply for the final CellCut biomedical device beta testing cycle or inquire about future opportunities within the CLYTE First Client Initiative. Help advance biomedical research and biomedical innovations.

Click Here to sign up!